Literature DB >> 6832828

Protection against pneumococcal infection in mice conferred by phosphocholine-binding antibodies: specificity of the phosphocholine binding and relation to several types.

S C Szu, S Clarke, J B Robbins.   

Abstract

Some anti-phosphocholine antibodies protect mice against challenge with certain, but not all, pneumococcal types. We found that both their isotype and reactivity with the cell wall C-polysaccharide of encapsulated pneumococci, as measured by immunodiffusion, were important in predicting the protective activity of anti-phosphocholine antibodies. We propose that the specificity of the protective antibodies includes the backbone of the phosphocholine-containing structure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6832828      PMCID: PMC348048          DOI: 10.1128/iai.39.2.993-999.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

Review 1.  The interaction of homogeneous, murine myeloma immunoglobulins with polysaccharide antigens.

Authors:  C P Glaudemans
Journal:  Adv Carbohydr Chem Biochem       Date:  1975       Impact factor: 12.200

2.  Specificity for phosphorylcholine of six murine myeloma proteins reactive with Pneumococcus C polysaccharide and beta-lipoprotein.

Authors:  M A Leon; N M Young
Journal:  Biochemistry       Date:  1971-04-13       Impact factor: 3.162

3.  Capsulation of pneumococcus with soluble cell wall-like polysaccharide. II. Nonidentity of cell wall and soluble cell wall-like polysaccharides derived from the same and from different pneumococcal strains.

Authors:  G Schiffman; D L Bornstein; R Austrian
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

4.  Binding studies with antibodies having phosphorylcholine specificity and fragments derived from their homologous Streptococcus pneumoniae type 27 capsular polysaccharide.

Authors:  L G Bennett; C P Glaudemans
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

5.  Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody.

Authors:  J Yother; C Forman; B M Gray; D E Briles
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

6.  Pneumococcal C-substance, a ribitol teichoic acid containing choline phosphate.

Authors:  D E Brundish; J Baddiley
Journal:  Biochem J       Date:  1968-12       Impact factor: 3.857

7.  Clonotypes of anti-phosphocholine antibodies induced with Proteus morganii (Potter). II. Heterogeneity, class, and idiotypic analyses of the repertoires in BALB/c and A/HeJ mice.

Authors:  K R Williams; J L Claflin
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

8.  IMMUNIZATION OF EXPERIMENTAL ANIMALS WITH A SOLUBLE ANTIGEN EXTRACTED FROM PNEUMOCOCCI.

Authors:  R J Dubos
Journal:  J Exp Med       Date:  1938-04-30       Impact factor: 14.307

9.  ACTIVE AND PASSIVE IMMUNITY TO PNEUMOCOCCUS INFECTION INDUCED IN RABBITS BY IMMUNIZATION WITH R PNEUMOCOCCI.

Authors:  W S Tillett
Journal:  J Exp Med       Date:  1928-11-30       Impact factor: 14.307

10.  Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model.

Authors:  C E Frasch; L Parkes; R M McNelis; E C Gotschlich
Journal:  J Exp Med       Date:  1976-08-01       Impact factor: 14.307

View more
  28 in total

1.  Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci.

Authors:  S C Szu; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

2.  Induction of anti-pneumococcal cell wall polysaccharide antibodies by type 4 pneumococcal polysaccharide-protein conjugates.

Authors:  C Peeters; A M Tenbergen-Meekes; J Poolmann; B Zegers; G Rijkers
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

Review 3.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

4.  Differences in virulence for mice among Streptococcus pneumoniae strains of capsular types 2, 3, 4, 5, and 6 are not attributable to differences in pneumolysin production.

Authors:  K A Benton; J C Paton; D E Briles
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

5.  Dissociation between enhanced resistance and delayed hypersensitivity induced with subcellular preparations from Listeria monocytogenes and the adjuvant dimethyl-dioctadecyl-ammonium bromide.

Authors:  A C Antonissen; P J Lemmens; J F van den Bosch; C P van Boven
Journal:  Antonie Van Leeuwenhoek       Date:  1986       Impact factor: 2.271

6.  Production of interleukin-1 but not tumor necrosis factor by human monocytes stimulated with pneumococcal cell surface components.

Authors:  I Riesenfeld-Orn; S Wolpe; J F Garcia-Bustos; M K Hoffmann; E Tuomanen
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

7.  Determination of antibodies to pneumococcal C polysaccharide in patients with community-acquired pneumonia.

Authors:  H Holmberg; A Krook; A M Sjögren
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948

8.  Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens.

Authors:  D E Briles; C Forman; J C Horowitz; J E Volanakis; W H Benjamin; L S McDaniel; J Eldridge; J Brooks
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

9.  Correlation of serum opsonins with in vitro phagocytosis of Streptococcus pneumoniae.

Authors:  D S Chudwin; S G Artrip; A Korenblit; G Schiffman; S Rao
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

10.  Pneumococcal capsular polysaccharide structure predicts serotype prevalence.

Authors:  Daniel M Weinberger; Krzysztof Trzciński; Ying-Jie Lu; Debby Bogaert; Aaron Brandes; James Galagan; Porter W Anderson; Richard Malley; Marc Lipsitch
Journal:  PLoS Pathog       Date:  2009-06-12       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.